Welcome to LookChem.com Sign In|Join Free

CAS

  • or

101083-92-5

Post Buying Request

101083-92-5 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

101083-92-5 Usage

Uses

5-Nitro-1H-pyrrolo[2,3-b]pyridine is a reagent used in the synthesis of Cdc7 kinase inhibitors used as a novel cancer therapy. Also an intermediate in the synthesis of 4-anilinoquinazolines as potential anticancer agents.

Check Digit Verification of cas no

The CAS Registry Mumber 101083-92-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,1,0,8 and 3 respectively; the second part has 2 digits, 9 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 101083-92:
(8*1)+(7*0)+(6*1)+(5*0)+(4*8)+(3*3)+(2*9)+(1*2)=75
75 % 10 = 5
So 101083-92-5 is a valid CAS Registry Number.
InChI:InChI=1/C7H5N3O2/c11-10(12)6-3-5-1-2-8-7(5)9-4-6/h1-4H,(H,8,9)

101083-92-5 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Alfa Aesar

  • (H33141)  5-Nitro-7-azaindole, 97%   

  • 101083-92-5

  • 250mg

  • 605.0CNY

  • Detail
  • Alfa Aesar

  • (H33141)  5-Nitro-7-azaindole, 97%   

  • 101083-92-5

  • 1g

  • 1677.0CNY

  • Detail

101083-92-5SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 14, 2017

Revision Date: Aug 14, 2017

1.Identification

1.1 GHS Product identifier

Product name 5-Nitro-7-azaindole

1.2 Other means of identification

Product number -
Other names 5-Nitro-1H-pyrrolo[2,3-b]pyridine

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:101083-92-5 SDS

101083-92-5Relevant articles and documents

Efficient and Scalable Process for Synthesis of 5-Nitro-7-azaindole

Bhat, Prasanna V.,Dere, Ravindra T.,Ravikumar,Hindupur, Rama Mohan,Pati, Hari N.

, p. 1282 - 1285 (2015)

A simple and straightforward methodology for the synthesis of 5-nitro-7-azaindole 6 has been developed using metal-free cycloisomerization of 5-nitro-3-trimethylsilanylethynyl-pyridin-2-ylamine 18. Large-scale applicability of this newly developed method was successfully demonstrated on multikilogram scale to obtain 5-nitro-7-azaindole 6 in consistent yield and purity.

SUBSTITUTED FUSED TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF

-

, (2012/10/08)

The present invention relates to substituted fused tricyclic compounds of formula (I) or (Ia), their tautomers, polymorphs, stereoisomers, prodrugs, solvates, co-crystals, pharmaceutically acceptable salts, pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by JAK activity. The compounds of the present invention are useful in the treatment, prevention or suppression of diseases and disorders mediated by JAK activity. Such conditions include, but not limited to, arthritis, Alzheimer's disease, autoimmune thyroid disorders, cancer, diabetes, leukemia, T-cell prolymphocytic leukemia, lymphoma, myleoproliferation disorders, lupus, multiple myeloma, multiple sclerosis, osteoarthritis, sepsis, psoriatic arthritis, prostate cancer, T-cell autoimmune disease, inflammatory diseases, chronic and acute allograft transplant rejection, bone marrow transplant, stroke, asthma, chronic obstructive pulmonary disease, allergy, bronchitis, viral diseases, or Type I diabetes, complications from diabetes, rheumatoid arthritis, asthma, Crohn's disease, dry eye, uveitis, inflammatory bowel disease, organ transplant rejection, psoriasis and ulcerative colitis. The present disclosure also relates to process for the preparation of such compounds, and to pharmaceutical compositions containing them.

Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them

-

Page/Page column 36, (2010/11/27)

The present invention is directed to compounds of the formula or pharmaceutically acceptable salts, prodrug, solvate or optical isomer thereof, pharmaceutical compositions containing same and use thereof for treating diseases linked to disregulated cell p

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 101083-92-5